Provider: View Press Release
Type: Link
Title: Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults | GSK
Description: Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time
Provider: View Press Release
Type: Link
Title: European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention | GSK
Description: Cabotegravir demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV in clinical trials.
Provider: View Press Release
Type: Link
Title: Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | GSK
Description: Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
Provider: View Press Release
Type: Link
Title: GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine | GSK
Description: GSK and Save the Children renew their 10-year partnership for a further five years.
Provider: View Press Release
Type: Link
Title: GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator | GSK
Description: Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia
Provider: View Press Release
Type: Link
Title: GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps | GSK
Description: If approved, Nucala would be first anti-interleukin-5 biologic available in Japan for treatment of adults with CRSwNP